Here, we presented an EGFRL858R/T790M/FGFR1 dual-inhibitor 15c, which can simultaneous inhibited the kinase activity of EGFRL858R/T790M and FGFR1 both in kinase assay and cell study, for the treatment of FGFR1-amplified EGFR-TKIs resistant lung cancers. Here, FGFR1 is linked to lung carcinoma.